Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2016-08-30Clinical Trial Update: Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia
An in vitro study assessing tigecycline as a potential treatment for chronic myeloid leukemia. The investigation explores tigecycline's acti…
-
FDA approval · 2016-08-25FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GLEEVEC (imatinib mesylate) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2016-08-22Clinical Trial Update: OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy) [Phase 2]
A Phase 2 trial of dasatinib as optimized monotherapy for BCR-ABL positive chronic myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2016-08-19Clinical Trial Update: Umbilical Cord Blood Transplant for Hematological Malignancies [Phase 1]
Phase 1 clinical trial evaluating umbilical cord blood transplantation for hematologic malignancies has completed enrollment and reporting.
-
FDA approval · 2016-08-17FDA Approved: IMATINIB MESYLATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves Teva's supplemental application for imatinib mesylate, a generic version of the cancer drug, to update its approval status.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-08-16Clinical Trial Update: Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) [Phase 3]
Phase 3 trial comparing nilotinib versus standard imatinib in chronic-phase chronic myeloid leukemia; study evaluated kinetics of complete m…
-
CLINICAL_TRIALS withdrawal · 2016-08-15Clinical Trial Update: Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating imatinib in combination with the CXCR4 antagonist BL-8040 for improving molecular response in chronic …
-
CLINICAL_TRIALS trial_result · 2016-08-12Clinical Trial Update: An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia [Phase 1]
This is a Phase 1 ascending-dose study of KW-2449 in patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syn…
-
CLINICAL_TRIALS trial_result · 2016-08-05Clinical Trial Update: Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML) [Phase 3]
An update on a Phase 3 expanded-access study of peginterferon alfa-2a (Pegasys) for chronic myeloid leukemia, with results posted in 2016.
-
FDA approval · 2016-08-04FDA Approved: IMATINIB MESYLATE — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approval of Teva's Imatinib Mesylate Original Application under ANDA204285 for a generic Imatinib product.
-
CLINICAL_TRIALS withdrawal · 2016-07-14Clinical Trial Update: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies [Phase 2]
A Phase 2 clinical trial evaluating single or double donor umbilical cord blood transplant for high-risk hematologic malignancies has been w…
-
CLINICAL_TRIALS trial_result · 2016-07-11Clinical Trial Update: Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
This entry notes the completion of a non-interventional treatment-patterns study in chronic phase chronic myeloid leukemia, sponsored by Bri…
-
CLINICAL_TRIALS trial_result · 2016-07-04Clinical Trial Update: Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa [Phase 3]
A Phase 3 trial comparing homoharringtonine with hydroxyurea for chronic myeloid leukemia that has not responded to interferon alfa has been…
-
CLINICAL_TRIALS trial_result · 2016-07-01Clinical Trial Update: Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia [Phase 1, Phase 2]
A completed Phase 1/2 safety study evaluating CLT-008 (human myeloid progenitor cells) in patients with various leukemias after chemotherapy…
-
CLINICAL_TRIALS trial_result · 2016-06-16Clinical Trial Update: Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
A Stanford-sponsored clinical trial evaluating allogeneic transplantation for acute and chronic leukemias has been terminated.
-
FDA approval · 2016-06-10FDA Approved: DASATINIB — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original generic application for dasatinib (DASATINIB). The approval provides a generic version of dasatinib for…
-
FDA label_change · 2016-06-02FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ICLUSIG (ponatinib hydrochloride) from Takeda Pharmaceuticals America, Inc. The approval updates…
-
CLINICAL_TRIALS trial_result · 2016-05-11Clinical Trial Update: Late Chronic Phase Chronic Myelogenous Leukemia [Phase 2]
A Phase 2 clinical trial evaluating treatment for late chronic phase chronic myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2016-05-11Clinical Trial Update: High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) [Phase 3]
A Phase 3 study evaluated high-dose imatinib (Gleevec) given alone or in combination with pegylated interferon alfa-2b (Peg-Intron) and GM-C…
-
CLINICAL_TRIALS other · 2016-05-11Clinical Trial Update: Radotinib as 3rd or Later Line Therapy in CP-CML [Phase 2]
This report notes a Phase 2 clinical trial of radotinib as third- or later-line therapy for chronic phase chronic myeloid leukemia (CP-CML).…
-
CLINICAL_TRIALS trial_result · 2016-05-06Clinical Trial Update: Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies [Phase 2]
Phase 2 trial evaluating a conditioning regimen of fludarabine phosphate, busulfan, and anti-thymocyte globulin followed by donor peripheral…
-
CLINICAL_TRIALS trial_result · 2016-05-02Clinical Trial Update: Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation [Phase 2]
Phase 2 clinical trial evaluating repeat transplantation for relapsed or refractory hematologic malignancies after prior transplant; the stu…
-
CLINICAL_TRIALS trial_result · 2016-04-21Clinical Trial Update: Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) [Phase 1]
Phase 1 study evaluating imatinib mesylate and the pharmacokinetics of acetaminophen in patients with newly diagnosed chronic myeloid leukem…
-
CLINICAL_TRIALS trial_result · 2016-04-20Clinical Trial Update: Nilotinib Pre and Post Allogeneic Stem Cell Transplantation [Phase 2]
Phase 2 trial evaluating nilotinib given before and after allogeneic stem cell transplantation in chronic myeloid leukemia and acute lymphob…
-
CLINICAL_TRIALS withdrawal · 2016-04-20Clinical Trial Update: Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders
A clinical trial (NCT02663648) evaluating a cell cycle regulatory gene study in myeloproliferative neoplasms has been withdrawn by the spons…